Afirma
GENOMIC SEQUENCING CLASSIFIER

VV20030

REPORT STATUS: Final
PAGES: 1 of 1
CLIENT ID: 97
AFIRMA REQ: R123

PATIENT REPORT

PATIENT INFORMATION

PATIENT: John Doe | **DOB:** 01 Jan 1973 | **GENDER:** M | **LAB ID:** L123 | **MRN:** M123

COLLECTION DATE	03 Jun 2018	**FACILITY NAME**	University Hospital of Anytown		
RECEIVED DATE	05 Jun 2018	**SUBMITTING PHYSICIAN**	Jane Demo	**PHONE**	(555) 555-5555
REPORT DATE	06 Jun 2018	**TREATING PHYSICIAN/CC**	---	**PHONE**	---

CLINICAL HISTORY: No Clinical History Provided

RESULTS SUMMARY

NODULE	CYTOPATHOLOGY	AFIRMA GSC	MALIGNANCY CLASSIFIERS	XPRESSION ATLAS
A	---	Benign (ROM 4%[1])	Negative	N/A



RESULTS DETAILS

NODULE A	**SIZE:** 1.5 cm **LOCATION:** Upper Right
AFIRMA GSC RESULT	**Benign**
MALIGNANCY CLASSIFIERS RESULTS	**Negative**: *BRAF* p. V600E c. 1799T>A, MTC **Not Detected**: *RET/PTC1*, *RET/PTC3*
MALIGNANCY CLASSIFIERS COMMENTS	MTC and *BRAF* malignancy classifier results were negative and *RET/PTC1* and *RET/PTC3* were not detected. These results do not change the risk of malignancy (ROM) of the Afirma GSC Benign result.
GROSS DESCRIPTION	Received one vial of FNAprotect, labeled with the Requisition Form # and patient initials.

RESULTS INTERPRETATION

Afirma GSC[1,5]	**Cytopathology Diagnosis Indeterminate**[§]
Risk of Malignancy: **Afirma GSC Benign**	4%
Risk of Malignancy: **Afirma GSC Suspicious**	~50%
Sensitivity:	91%
Specificity:	68%
Limit of Detection[†]:	5%

	Malignancy Classifiers			
	MTC[3,8]	***BRAF***[‡2,4,8]	***RET/PTC***[2,8]	**Parathyroid**[6,8]
Sensitivity/Specificity	>99% / >99%			>99% / >99%
PPA/NPA		>99% / >99%		
Confirmation Rate/NPA			>99% / >99%	
Risk of Malignancy	>99%	>95%	>95%	
Limit of Detection[†]	20%	5%	10%	15%

References: 1. Patel KN, et al. WCTC 2017. 2. Haugen BR, et al. *Thyroid* 2016. 3. Randolph G, et al. ATA 2017 4. Angell TE, et al. ATA 2017. 5. Hu Z, et al. ATA 2017. 6. Sosa JA, et al. ATA 2017. 8. Data on file.

§ Indeterminate includes Atypia of Undetermined Significance / Follicular Lesion of Undetermined Significance and (suspicious for) Follicular Neoplasm / Hürthle Cell Neoplasm.
† Analytical sensitivity studies demonstrated the test's ability to detect malignant cells in a background of benign cells.
‡ *BRAF* classifier performance is based on a comparison to a castPCR DNA assay for the *BRAF* V600E mutation.

Afirma Thyroid FNA Analysis is a diagnostic service provided by Veracyte, Inc. for the assessment of thyroid nodules that includes cytopathology and gene expression testing. Afirma GSC, *BRAF*, MTC and *RET/PTC* tests and their performance characteristics were determined by Veracyte. MTC is an RNA classifier that identifies the presence of medullary thyroid carcinoma (MTC); *BRAF* is a *BRAF* p. V600E, c. 1799T>A RNA classifier; *RET/PTC* is a gene expression marker of somatic rearrangements of the *RET* protooncogene (*RET/PTC1* and *RET/PTC3*).

E-SIGNED ON 06 Jun 2018 10:43 AM BY:
Robert J Monroe MD, PhD, Veracyte Inc. CLIA # 05D2014120
6000 Shoreline Ct, Suite 100, South San Francisco, CA 94080

CLIA#05D2014120
CA License CLF340176
Lab Director: Robert J Monroe, MD, PhD

veracyte™

6000 Shoreline Court, Suite 100
South San Francisco, CA 94080
T 888.9AFIRMA (888.923.4762)
T 650.243.6350 (International)
F 650.243.6388
E support@veracyte.com